Tune in to the FREE "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Authors: Harding T, Swanson J, Van Ness B Abstract Multiple myeloma (MM) remains a largely incurable hematologic cancer due to an inability to broadly target inevitable drug-resistant relapse. Epigenetic abnormalities are abundantly present in multiple myeloma and have increasingly demonstrated critical roles for tumor development and relapse to standard therapies. Accumulating evidence suggests that the histone methyltransferase EZH2 is aberrantly active in MM. We tested the efficacy of EZH2 specific inhibitors in a large panel of human MM cell lines (HMCLs) and found that only a subset of HMCLs demonstrate single...
The International Myeloma Working Group recommends that FISH be performed on specifically identified plasma cells (PCs). A number of different genomic abnormalities are associated with multiple myeloma (MM), the detection of which, by conventional karyotyping and FISH, is limited by the percentage of PCs in the specimen.
FISH testing for plasma cell neoplasms is a common bottleneck in laboratory workflows. CD138+ enrichment is often required to improve sensitivity, yet still may yield insufficient or poor quality cells, and possibly, false negative results. Our current Multiple Myeloma panel (MMP) is designed as a reflex test, in which IGH break-apart (IGH-BAP) and t(11;14) results direct subsequent testing for t(4;14) and t(14;16). While cost-effective, this strategy can be problematic, particularly for CD138+ sorted samples.
Publication date: August 2018 Source:Cancer Genetics, Volumes 224–225 Author(s): Leena Gole, Constance Chua, Yvoonne Tan, Shirley Chan, Teck Guan Soh, Lip Kun Tan, Wee Joo Chng, Xiaoli Sun
Journal of Gastroenterology and Hepatology, EarlyView.
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma, Published online: 11 May 2018; doi:10.1038/s41408-018-0075-6Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
In conclusion our results indicate that TIFA functions as a key transducer in DNA damage–induced NF-κB activation.
Authors: Jin HG, Wu GZ, Wu GH, Bao YG Abstract Rapamycin is known to inhibit the mammalian target of rapamycin complex (mTORC)1 signaling pathway, but it is unable to effectively inhibit mTORC2, resulting in activation of protein kinase B in multiple myeloma (MM) cell lines. Additionally, certain studies have suggested that resveratrol has an effect on human MM cells, and that rapamycin in combination with resveratrol may be useful in cancer therapy. The present study aimed to investigate the combined treatment effect of resveratrol and rapamycin on the MM MM1.S cell line. The results demonstrated that combined tre...
Authors: Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X, Cong H Abstract Multiple myeloma (MM), accounting for ~1% of all types of human cancer and 13% of all hematological malignancies, is characterized by the malignant proliferation of monoclonal plasma cells (PCs) in the bone marrow. MM leads to end stage organ impairment, including bone lesions, renal dysfunction, hypercalcemia and anemia. So far, the specific pathogenesis of MM remains unclear and no early-stage sensitive biomarker of MM has been well characterized. Furthermore, treating MM is difficult, as the majority of patients eventually relapse or become ref...